Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

105.07 +0.72 (+0.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. 
Via Benzinga
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Axsome Therapeutics
Via Benzinga
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies. 
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
You can get in early on these potential winners. 
Via The Motley Fool
Axsome Therapeutics to Present at Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Riding the Wave: 3 Stocks That Can 10X by 2025
Are you looking to invest in stocks with the potential to 10x? Here are three stocks that can 10x by 2025. 
Via InvestorPlace
Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now
Now, you can scoop up these future growth winners for a bargain. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Neither has performed well on the stock market this year. 
Via The Motley Fool
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Axsome Therapeutics
Via Benzinga
3 No-Brainer Stocks to Buy Right Now for Less than $100
You can start with a small investment and win big over time. 
Via The Motley Fool
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
Axsome to host conference call and webcast on Monday, Nov. 6, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
From Axsome Therapeutics, Inc.
Via GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months. 
Via The Motley Fool
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
Today's market loser could be tomorrow's market winner. 
Via The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good. 
Via The Motley Fool
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
3 Explosive Stocks to Buy Right Now
These stocks are poised to pop in the not-too-distant future. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.